OnCusp Therapeutics Receives FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer
PRINCETON, N.J., Feb. 12, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today...
HKMU receives precious manuscripts and relics from Eileen Chang, Stephen Soong and Mae Fong Soong; Literary treasures to be digitally preserved to promote modern Chinese literature research
HONG KONG, Feb. 12, 2025 /PRNewswire/ -- This year marks the 30th anniversary of the passing of renowned Chinese writer Eileen Chang, who has a significant place in the modern Chinese literary world. Hong Kong Metropolitan University (HKMU) is...
Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma
SINGAPORE, Feb. 12, 2025 /PRNewswire/ -- On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an...
BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed Class 1...
Forest City Receives One More Good News, Digital Status Empowers Regional Development
ISKANDAR PUTERI, Malaysia, Feb. 6, 2025 /PRNewswire/ -- In recent years, Malaysian government has elevated the digital economy to a national strategic height, aimed at attracting companies, talent, and investment. Aerial view of Forest City Island 1...
Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 5, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody...
Four Seasons Education Receives Non-Compliance Letter from NYSE Regarding Holders Requirements
SHANGHAI, Feb. 3, 2025 /PRNewswire/ -- Four Seasons Education (Cayman) Inc. ("Four Seasons Education" or the "Company") (NYSE: FEDU), a tourism and education-related service provider in China, today announced that it has received a letter from the...
Axcelis Wins The 2024 SK hynix CSO Safety and Health Award
Award Recognizes Companies Who Achieve Highest Level of Safety BEVERLY, Mass., Feb. 3, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, has...
ICR Receives Unconditional ICROA Endorsement, Solidifying Commitment to High Integrity Carbon Credits
REYKJAVIK, Iceland, Jan. 31, 2025 /PRNewswire/ -- The International Carbon Registry (ICR) has received unconditional endorsement of its carbon crediting program by the International Carbon Reduction and Offset Alliance (ICROA).This achievement...
Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
SYDNEY, Jan. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and...